Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
All 12 treated children with NTKR, ROS1 or ALK gene abnormalities showed partial or compete tumor shrinkage.
An ongoing study is assessing pediatric and young adult cancers that did not respond to initial treatments.
The vaccine, based on an individual’s own tumor cells, improved survival time and proved safe in an early-stage trial.
Join us Sunday, April 28, 2019, to raise money, awareness, and connectedness with and for the National Brain Tumor Society!
While her response is not average, doctors say it represents a step forward for people with diffuse midline gliomas, a rare cancer.
Angela J. Waanders, MD, MPH, is tackling pediatric brain cancer.
A new breed of patient advocate is reshaping the future of cancer research.
Cancer organizations and the Food and Drug Administration want to broaden eligibility criteria for cancer clinical trials.
Adam Hayden is a 36-year-old philosopher, advocate and writer who lives in Indianapolis with his wife and three sons.
I recognize that I feel powerless. Without claiming too much, I imagine my spouse to feel powerless, too.
“More of these studies are needed to make progress in…precision, or personalized, medicine,” said NCI’s Konstantin Salnikow, PhD.
An interview with researcher Mario Suvà, MD, PhD
One participant in an ongoing clinical trial of a checkpoint inhibitor had her brain tumor completely disappear.
I’ve raised before the issue of talking to kids about cancer, but we face a combination of factors that affects our kids in untold ways.
Each year more than 23,000 people in the United States are diagnosed with brain cancer
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.